Completed PHASE1 INTERVENTIONAL 1-arm NCT00629733

Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of a New Ultra Low Molecular Weight Heparin (RO-14) Administered Subcutaneously Increasing Single-doses to Healthy Male Volunteers

Sponsor: Rovi Pharmaceuticals Laboratories

Conditions Healthy

Interventions RO-14

Updated 5 times since 2017 Last updated: Jun 7, 2011 Started: Dec 31, 2007 Primary completion: Dec 31, 2007 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. Rovi Pharmaceuticals Laboratories leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Rovi Pharmaceuticals Laboratories

Data source: Rovi Pharmaceuticals Laboratories

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Barcelona, Spain